Trk Dvr @ffdrobin

Dave: I appreciate the measured forecasts and information you provide. As a stockholder sitting around $77 I'm surprised at the stock reaction to the Neutron delay news. Isn't there a R&D budget to allow for this type of thing? They've diversified so are making money.

$ADMA Lily contract award with US Govt was announced 10/28. The trial pause was announced 10/13. Lily doesn't collect plasma or harvest the antibody, ADMA does.

@mihamiha When was that pause announced. Govt announcement of the $347m contract was on 10/28

@cashflowjreed Well as soon as this EUD is granted by FDA for the govt to buy and dispense this drug, other institutions will be able to as well. ADMA has a IP process for capturing the antibody which will make it very competiti... stocktwits.com/TrkDvr/message…

$ADMA Looks like Covid 19 convalescent anti-body treatment is making a comeback. Eli Lily has just been awarded a $375 m contract to supply 300K vials to the US govt.

@goodatlosing @StackDatCheez I think you made a good call. Risk & reward are the opposite sides of the same coin. Been there done that and wish you luck. I'm in 12K shares and would buy more if I had some available funds.

@saif3393 Go to Yahoo Finance and scroll down the summary section. You'll see the announcement of J Code approval on Oct 1 2020

@saif3393 I can't tell you where that is but if you read or listen to the last Q report, they make mention of the fact as well as their new J coding which is a big deal as far as reimbursements are concerned.

@GreenAndMean I'm in at about $1.42 with 10K shares. I remain bullish on this stock with all the fundamentals like, J coding for medicare etc, distribution channels, reorder sizes etc. Great buying opportunity if I had more cash available.

$BXRX Company has a large institutional sponsorship. The last selloff occurred in August and immediately replaced by others. I holding with these guys.

$BXRX Company has a large institutional sponsorship with the last sale by BlackRock back in June of 25K shares. I'm holding with these guys.

$BXRX Short volume has gone from 1.8m to 300K (30%) over the past 4 days. Unfortunately this impact has a snowballing effect. The discipline here is to not let the bears establish the narrative, hold steady and take advantage of the buying opportunity.

Short volume has been running from 1.8m shares to 300K shares over the past 4 days. Sadly this has an effect of dominos falling. The discipline here is to ignore their narrative, hold steady and use it as a buying opportunity.

$BXRX I think it would be appropriate for IR to confirm that the 9m shares issued are restricted from being traded thru 4/21

$TLGT I'm trying to build a case to justify buying more stock. The float is 3.47 mil with short volume of 5.4m on 21st & 2.8 mil on 22nd. This supports the price drop. The shorts make money when they buy back and it looks like ... stocktwits.com/TrkDvr/message…

@banksyhodler Yep, I started buying at $1.62 after the R/S. Back in with 20K at .80. Let see what happens this time.

$TLGT Took a $20K hit on this yesterday. I'll be back at .75 or so to get my money back.

@simbasana1 Probably a couple of traders decided to start pushing it and then it caught on. Any low float stock is likely to have this occur without any particular catalyst

$BXRX Keep in mind the dilution only takes effect in 6 months when shares can be traded. Considering the market acceptance of the the drug seems like a good opportunity to make lemonade.

Keep in mind the 9 mil shares just added can't be traded for 6 months. With the rollout of Anjeso this looks like a great opportunity to make lemonade!